Drugs / Autologous CD19-STAR-T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05631912 | Jun 2023 → Dec 2024 | B-cell non-Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19-STAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05631912 ↗ |
| Modality | Cell therapy | “autologous CD19-targeting STAR-T cell therapy” NCT05631912 ↗ |
| Target | CD19 | “anti-CD19-STAR construct” NCT05631912 ↗ |